12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Distinct antibody responses of patients with mild and severe leptospirosis determined by whole proteome microarray analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Leptospirosis is an important zoonotic disease worldwide. Humans usually present a mild non-specific febrile illness, but a proportion of them develop more severe outcomes, such as multi-organ failure, lung hemorrhage and death. Such complications are thought to depend on several factors, including the host immunity. Protective immunity is associated with humoral immune response, but little is known about the immune response mounted during naturally-acquired Leptospira infection.

          Methods and principal findings

          Here, we used protein microarray chip to profile the antibody responses of patients with severe and mild leptospirosis against the complete Leptospira interrogans serovar Copenhageni predicted ORFeome. We discovered a limited number of immunodominant antigens, with 36 antigens specific to patients, of which 11 were potential serodiagnostic antigens, identified at acute phase, and 33 were potential subunit vaccine targets, detected after recovery. Moreover, we found distinct antibody profiles in patients with different clinical outcomes: in the severe group, overall IgM responses do not change and IgG responses increase over time, while both IgM and IgG responses remain stable in the mild patient group. Analyses of individual patients’ responses showed that >74% of patients in the severe group had significant IgG increases over time compared to 29% of patients in the mild group. Additionally, 90% of IgM responses did not change over time in the mild group, compared to ~51% in the severe group.

          Conclusions

          In the present study, we detected antibody profiles associated with disease severity and speculate that patients with mild disease were protected from severe outcomes due to pre-existing antibodies, while patients with severe leptospirosis demonstrated an antibody profile typical of first exposure. Our findings represent a significant advance in the understanding of the humoral immune response to Leptospira infection, and we have identified new targets for the development of subunit vaccines and diagnostic tests.

          Author summary

          Leptospirosis is zoonotic disease of global importance, with over a million cases and nearly 60,000 deaths annually. Symptomatic disease presentation ranges from a mild febrile disease with non-specific symptoms to severe forms, characterized by multi-organ failure, lung hemorrhage, and death. Factors driving severe outcomes remain unclear, but the host immune response likely plays an important role. In the present study, we applied high throughput techniques to identify the antibody profiles of patients with severe and mild leptospirosis. We discovered a limited number of immunodominant antigens, specific to patients. Surprisingly, we found the antibody repertoire varies in patients with different clinical outcomes and hypothesized that patients with mild symptoms were protected from severe disease due to pre-existing antibodies, while the profile of patients with severe outcomes was representative of a first exposure. These findings represent a substantial step forward in the knowledge of the humoral immune response to Leptospira infection, and we have identified new targets for vaccine and diagnostic test development.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Leptospirosis: a zoonotic disease of global importance.

          In the past decade, leptospirosis has emerged as a globally important infectious disease. It occurs in urban environments of industrialised and developing countries, as well as in rural regions worldwide. Mortality remains significant, related both to delays in diagnosis due to lack of infrastructure and adequate clinical suspicion, and to other poorly understood reasons that may include inherent pathogenicity of some leptospiral strains or genetically determined host immunopathological responses. Pulmonary haemorrhage is recognised increasingly as a major, often lethal, manifestation of leptospirosis, the pathogenesis of which remains unclear. The completion of the genome sequence of Leptospira interrogans serovar lai, and other continuing leptospiral genome sequencing projects, promise to guide future work on the disease. Mainstays of treatment are still tetracyclines and beta-lactam/cephalosporins. No vaccine is available. Prevention is largely dependent on sanitation measures that may be difficult to implement, especially in developing countries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen.

            Leptospirosis is a zoonotic disease that has emerged as an important cause of morbidity and mortality among impoverished populations. One hundred years after the discovery of the causative spirochaetal agent, little is understood about Leptospira spp. pathogenesis, which in turn has hampered the development of new intervention strategies to address this neglected disease. However, the recent availability of complete genome sequences for Leptospira spp. and the discovery of genetic tools for their transformation have led to important insights into the biology of these pathogens and their pathogenesis. We discuss the life cycle of the bacterium, the recent advances in our understanding and the implications for the future prevention of leptospirosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Printing proteins as microarrays for high-throughput function determination.

              Systematic efforts are currently under way to construct defined sets of cloned genes for high-throughput expression and purification of recombinant proteins. To facilitate subsequent studies of protein function, we have developed miniaturized assays that accommodate extremely low sample volumes and enable the rapid, simultaneous processing of thousands of proteins. A high-precision robot designed to manufacture complementary DNA microarrays was used to spot proteins onto chemically derivatized glass slides at extremely high spatial densities. The proteins attached covalently to the slide surface yet retained their ability to interact specifically with other proteins, or with small molecules, in solution. Three applications for protein microarrays were demonstrated: screening for protein-protein interactions, identifying the substrates of protein kinases, and identifying the protein targets of small molecules.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Negl Trop Dis
                PLoS Negl Trop Dis
                plos
                plosntds
                PLoS Neglected Tropical Diseases
                Public Library of Science (San Francisco, CA USA )
                1935-2727
                1935-2735
                31 January 2017
                January 2017
                : 11
                : 1
                : e0005349
                Affiliations
                [1 ]Fiocruz, Bio-Manguinhos, Brazilian Ministry of Health, Rio de Janeiro, RJ, Brazil
                [2 ]Fiocruz, Gonçalo Moniz Research Institute, Brazilian Ministry of Health, Salvador, BA, Brazil
                [3 ]Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America
                [4 ]Antigen Discovery Inc, Irvine, CA, United States of America
                [5 ]Department of Medicine, Division of Infectious Disease, University of California Irvine, Irvine, California, United States of America
                [6 ]Institute of Collective Health, Federal University of Bahia, Salvador, BA, Brazil
                University of California San Diego School of Medicine, UNITED STATES
                Author notes

                I have read the journal’s policy and have the following conflicts: PLF receives income from Antigen Discovery, Inc., which is developing products related to the research described in this paper. The terms of this arrangement have been reviewed and approved by the University of California, Irvine in accordance with its conflict of interest policies. This does not alter our adherence to all PLOS policies on sharing data and materials.

                • Conceptualization: CLA EW AIK MAM PLF.

                • Formal analysis: CLA JCL AR.

                • Funding acquisition: PLF AIK.

                • Investigation: CLA JP RN AJ JSC AOD.

                • Methodology: PLF.

                • Project administration: PLF AIK.

                • Resources: EW NN GSR FC JEH MGR AIK MAM PLF.

                • Supervision: PLF AIK MAM.

                • Validation: CLA JCL AR.

                • Visualization: CLA.

                • Writing – original draft: CLA JCL.

                • Writing – review & editing: CLA JCL AR FC PLF.

                Article
                PNTD-D-16-01692
                10.1371/journal.pntd.0005349
                5302828
                28141801
                2eeb0312-8fe9-49e9-a8a2-bb062a90996f
                © 2017 Lessa-Aquino et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 14 September 2016
                : 22 January 2017
                Page count
                Figures: 4, Tables: 1, Pages: 17
                Funding
                Funded by: funder-id http://dx.doi.org/10.13039/100000002, National Institutes of Health;
                Award ID: U01AI088752
                Award Recipient :
                Funding was provided by NIH grant U01AI088752 (AIK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Medicine and Health Sciences
                Infectious Diseases
                Bacterial Diseases
                Leptospirosis
                Medicine and Health Sciences
                Tropical Diseases
                Neglected Tropical Diseases
                Leptospirosis
                Medicine and Health Sciences
                Infectious Diseases
                Zoonoses
                Leptospirosis
                Biology and Life Sciences
                Physiology
                Immune Physiology
                Antibodies
                Medicine and Health Sciences
                Physiology
                Immune Physiology
                Antibodies
                Biology and Life Sciences
                Immunology
                Immune System Proteins
                Antibodies
                Medicine and Health Sciences
                Immunology
                Immune System Proteins
                Antibodies
                Biology and Life Sciences
                Biochemistry
                Proteins
                Immune System Proteins
                Antibodies
                Research and Analysis Methods
                Bioassays and Physiological Analysis
                Microarrays
                Biology and Life Sciences
                Organisms
                Bacteria
                Leptospira
                Biology and Life Sciences
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Bacterial Pathogens
                Leptospira
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Pathogens
                Microbial Pathogens
                Bacterial Pathogens
                Leptospira
                Biology and Life Sciences
                Immunology
                Immune Response
                Antibody Response
                Medicine and Health Sciences
                Immunology
                Immune Response
                Antibody Response
                Medicine and Health Sciences
                Diagnostic Medicine
                Biology and Life Sciences
                Biochemistry
                Proteins
                Acute Phase Proteins
                Biology and Life Sciences
                Organisms
                Bacteria
                Leptospira
                Leptospira Interrogans
                Biology and Life Sciences
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Bacterial Pathogens
                Leptospira
                Leptospira Interrogans
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Pathogens
                Microbial Pathogens
                Bacterial Pathogens
                Leptospira
                Leptospira Interrogans
                Custom metadata
                vor-update-to-uncorrected-proof
                2017-02-10
                All protein microarray files are available from the GEO database (accession number GSE86630).

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article